Clinical Trial

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

Study acronym: HOVON134MF
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2022 (before its estimated July 2023 completion). Its status may not reflect the trial's current state.
Summary
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-08-23; most recent amendment 2022-08-19.
Status change: Recruiting → Active, Not Recruiting 2022-08-19
Trial Details
NCT Number NCT03645824
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators: Dutch Cancer Society, CTI BioPharma
Conditions Myelofibrosis
Enrollment 61 participants
Start Date 2018-06-04
Primary Completion 2023-07 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2022-08-22